Update on biology: Uric acid and the activation of immune and inflammatory cells

Current Rheumatology Reports

Volumn 12, Issue 2, 2010, Pages 135-141

  Martinon, Fabio ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Autoinflammation; Gout; Inflammasome; Innate immunity; Uric acid

Indexed keywords

17 DEMETHOXY 17 (2 DIMETHYLAMINOETHYLAMINO)GELDANAMYCIN; CANAKINUMAB; COLCHICINE; CORTICOSTEROID; CRYOPYRIN; CYTOCHALASIN D; INFLAMMASOME; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 8; MYELOBLASTIN; NONSTEROID ANTIINFLAMMATORY AGENT; REACTIVE OXYGEN METABOLITE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; THIOREDOXIN INTERACTING PROTEIN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; URIC ACID; VX 765;

AMYLOIDOSIS; CINCA SYNDROME; CRYSTALLIZATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; GOUT; HUMAN; HYPERURICEMIA; IMMUNOCOMPETENT CELL; INFLAMMATION; INFLAMMATORY CELL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHAGOCYTOSIS; POTASSIUM TRANSPORT; REVIEW;

ACUTE DISEASE; CRYSTALLIZATION; GOUT; HUMANS; IMMUNE SYSTEM; IMMUNITY, INNATE; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-1; URIC ACID;

EID: 77953475954     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-010-0092-3     Document Type: Review

References (45)

1. Doherty M: New insights into the epidemiology of gout. Rheumatology 2009, 48:ii2-ii8.
2. Richette P, Bardin T: Gout. Lancet 2010, 375:318-328.
3. Mandell BF: Clinical manifestations of hyperuricemia and gout. Cleve Clin J Med 2008, 75(Suppl 5):S5-S8.
4. Faires J, McCarty D: Acute arthritis in man and dog after intrasynovial injection of sodium. Lancet 1962, 280:682-685.
5. Neogi T: Asymptomatic hyperuricemia: perhaps not so benign? J Rheumatol 2008, 35:734-737.
6. Mcgill NW, Dieppe PA: Evidence for a promoter of urate crystal formation in gouty synovial fluid. Ann Rheum Dis 1991, 50:558-561.
7. Mcgill NW, Hayes A, Dieppe PA: Morphological evidence for biological control of urate crystal formation in vivo and in vitro. Scand J Rheumatol 1992, 21:215-219.
8. Kanevets U, Sharma K, Dresser K, Shi Y: A role of IgM antibodies in monosodium urate crystal formation and associated adjuvanticity. J Immunol 2009, 182:1912-1918.
9. Shi Y, Mucsi AD, Ng G: Monosodium urate crystals in inflammation and immunity. Immunol Rev 2010, 233:203-217.
10. Martin WJ, Harper JL: Innate inflammation and resolution in acute gout. Immunol Cell Biol 2010, 88:15-19. This is an excellent review focusing on the emerging role of mononuclear phagocytes in both the initiation and resolution of acute gout, and the interplay between monocytes and other elements of the innate immune response, including neutrophils, and complement protein activation.
11. Martin WJ, Walton M, Harper J: Resident macrophages initiating and driving inflammation in a monosodium urate monohydrate crystal-induced murine peritoneal model of acute gout. Arthritis Rheum 2009, 60:281-289.
12. Chen CJ, Shi Y, Hearn A, et al.: MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest 2006, 116:2262-2271.
13. Popa-Nita O, Naccache PH: Crystal-induced neutrophil activation. Immunol Cell Biol 2010, 88:32-40.
14. Shi Y, Evans JE, Rock KL: Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003, 425:516-521.
15. Shi Y, Galusha SA, Rock KL: Cutting edge: elimination of an endogenous adjuvant reduces the activation of CD8 T lymphocytes to transplanted cells and in an autoimmune diabetes model. J Immunol 2006, 176:3905-3908.
16. Kool M, Soullié T, Van Nimwegen M, et al.: Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 2008, 205:869-882.
17. Eisenbarth SC, Colegio OR, O'Connor W, et al.: Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008, 453:1122-1126.
18. Martinon F, Mayor A, Tschopp J: The inflammasomes: guardians of the body. Annu Rev Immunol 2009, 27:229-265.
19. Liu-Bryan R, Scott P, Sydlaske A, et al.: Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum 2005, 52:2936-2946.
20. Scott P, Ma H, Viriyakosol S, et al.: Engagement of CD14 mediates the inflammatory potential of monosodium urate crystals. J Immunol 2006, 177:6370-6378.
21. Ng G, Sharma K, Ward SM, et al.: Receptor-independent, direct membrane binding leads to cell-surface lipid sorting and Syk kinase activation in dendritic cells. Immunity 2008, 29:807-818. This study provides insight into receptor-independent signaling by MSUs.
22. Dostert C, Petrilli V, Van Bruggen R, et al.: Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008, 320:674-677.
23. Martinon F, Pétrilli V, Mayor A, et al.: Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241.
24. Stutz A, Golenbock DT, Latz E: Inflammasomes: too big to miss. J Clin Invest 2009, 119:3502-3511.
25. Martinon F, Burns K, Tschopp J: The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002, 10:417-426.
26. Sims JE, Smith DE: The IL-1 family: regulators of immunity. Nat Rev Immunol 2010, 10:89-102. This is an excellent review providing an updated overview of the biological activities of the IL-1 family.
27. Brodsky IE, Monack D: NLR-mediated control of inflammasome assembly in the host response against bacterial pathogens. Semin Immunol 2009, 21:199-207.
28. Schroder K, Zhou R, Tschopp J: The NLRP3 inflammasome: a sensor for metabolic danger? Science 2010, 327:296-300. This is an excellent essay discussing the possible role of the NLRP3 inflammasome in metabolic disorders, including T2DM.
29. Agostini L, Martinon F, Burns K, et al.: NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004, 20:319-325.
30. Mayor A, Martinon F, De Smedt T, et al.: A crucial function of SGT1 and HSP90 in inflammasome activity links mammalian and plant innate immune responses. Nat Immunol 2007, 8:497-503.
31. Martinon F: Mechanisms of uric acid crystal-mediated auto-inflammation. Immunol Rev 2010, 233:218-232.
32. Sautin YY, Nakagawa T, Zharikov S, Johnson RJ: Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol 2007, 293:C584-C596.
33. Zhou R, Tardivel A, Thorens B, et al.: Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 2010, 11:136-140. This study provided a significant advance in the understanding of NLRP3 activation. It identified TXNIP as a direct activator of NLRP3.
34. Coeshott C, Ohnemus C, Pilyavskaya A, et al.: Converting enzyme-independent release of tumor necrosis factor alpha and IL-1beta from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3. Proc Natl Acad Sci USA 1999, 96:6261-6266.
35. Joosten LA, Netea MG, Fantuzzi G, et al.: Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta. Arthritis Rheum 2009, 60:3651-3662. This study suggests a role for PR3-mediated IL-1 activation in vivo.
36. Rider TG, Jordan KM: The modern management of gout. Rheumatology 2010, 49:5-14.
37. Terkeltaub R: Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol 2010, 6:30-38.
38. Bardin T: Acute inflammatory arthritis: interleukin-1 blockade: a magic wand for gout? Nat Rev Rheumatol 2009, 5:594-596.
39. Masters SL, Simon A, Aksentijevich I, Kastner DL: Horror autoinflammaticus: the molecular pathophysiology of autoinflam-matory disease. Annu Rev Immunol 2009, 27:621-668.
40. Goldbach-Mansky R, Dailey NJ, Canna SW, et al.: Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006, 355:581-592.
41. Hawkins PN, Lachmann HJ, McDermott MF: Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 2003, 348:2583-2584.
42. Church LD, McDermott MF: Rilonacept in cryopyrin-associated periodic syndromes: the beginning of longer-acting interleukin-1 antagonism. Nat Clin Pract Rheumatol 2009, 5:14-15.
43. Terkeltaub R, Sundy JS, Schumacher HR, et al.: The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 2009, 68:1613-1617.
44. Lachmann HJ, Lowe P, Felix SD, et al.: In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med 2009, 206:1029-1036.
45. Stack JH, Beaumont K, Larsen PD, et al.: IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients. J Immunol 2005, 175:2630-2634.